According to the univariate analysis, a history of pulmonary disease, six laboratory parameters (platelet count, lymphocyte count, albumin level, lactate dehydrogenase level, C-reactive protein level, and sIL2R level), three factors related to lymphoma (Ann Arbor stage, extranodal involvement, and bone marrow infiltration), and a positive hepatitis panel were selected as candidate predictors of the occurrence of FN during the first cycle of R-CHOP-like therapy. The gene discussed is ALB; the disease is Hepatitis.